AU2017261371B2 - Method of treating lower tract urothelial cancer - Google Patents

Method of treating lower tract urothelial cancer Download PDF

Info

Publication number
AU2017261371B2
AU2017261371B2 AU2017261371A AU2017261371A AU2017261371B2 AU 2017261371 B2 AU2017261371 B2 AU 2017261371B2 AU 2017261371 A AU2017261371 A AU 2017261371A AU 2017261371 A AU2017261371 A AU 2017261371A AU 2017261371 B2 AU2017261371 B2 AU 2017261371B2
Authority
AU
Australia
Prior art keywords
gemcitabine
individual
bladder
antimetabolite
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017261371A
Other languages
English (en)
Other versions
AU2017261371A1 (en
Inventor
Vikas Agarwal
Christopher CUTIE
Dennis GIESING
Cheryl Larrivee-Elkins
Purnanand SARMA
Christopher SEARCY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taris Biomedical LLC
Original Assignee
Taris Biomedical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taris Biomedical LLC filed Critical Taris Biomedical LLC
Publication of AU2017261371A1 publication Critical patent/AU2017261371A1/en
Application granted granted Critical
Publication of AU2017261371B2 publication Critical patent/AU2017261371B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
AU2017261371A 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer Active AU2017261371B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US62/333,151 2016-05-06
US201762443614P 2017-01-06 2017-01-06
US62/443,614 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Publications (2)

Publication Number Publication Date
AU2017261371A1 AU2017261371A1 (en) 2018-12-13
AU2017261371B2 true AU2017261371B2 (en) 2023-07-06

Family

ID=60203435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017261371A Active AU2017261371B2 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP3452053B1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR20220123317A (enExample)
CN (2) CN109475571A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL295592A (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ787786A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG10201913416PA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2019023388A1 (en) * 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
PE20210041A1 (es) * 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056986A1 (en) * 2010-06-02 2014-02-27 Abraxis Bioscience, Llc Methods of treating bladder cancer
US20150165178A1 (en) * 2012-08-31 2015-06-18 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer
US20150216937A1 (en) * 2012-03-29 2015-08-06 Altor Bioscience Corporation Methods for treating neoplasia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US8343516B2 (en) 2009-06-26 2013-01-01 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US8679094B2 (en) 2009-12-17 2014-03-25 Taris Biomedical, Inc. Implantable device with intravesical tolerability and methods of treatment
PT2600800T (pt) 2010-08-05 2020-11-05 Taris Biomedical Llc Dispositivo de administração de drogas por stent ureteral, kit e método
WO2012106714A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
KR102383496B1 (ko) 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
EP2968120A1 (en) 2013-03-15 2016-01-20 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2015026813A1 (en) 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
HRP20251264T1 (hr) * 2014-03-06 2025-12-05 Taris Biomedical Llc Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
KR102391761B1 (ko) 2014-06-26 2022-04-27 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140056986A1 (en) * 2010-06-02 2014-02-27 Abraxis Bioscience, Llc Methods of treating bladder cancer
US20150216937A1 (en) * 2012-03-29 2015-08-06 Altor Bioscience Corporation Methods for treating neoplasia
US20150165178A1 (en) * 2012-08-31 2015-06-18 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
":A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225mg in subjects with non-muscle invasive urothelial carcinoma of the bladder NCT02720367 (Clinical Trials Identifier). *
BIDNUR, S. ET AL.: "Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer", BLADDER CANCER, vol. 2, no. 1, 7 January 2016 (2016-01-07), pages 15 - 25, XP055439493 *
COCKERILL, P. A. et al., 'Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle invasive bladder cancer.' BJU Int. 2016 Mar; 117(3):456-62 Epub 2015 May 23 *
JIANXING LI, WANG QI, XIAO BO, ZHANG XIN: "Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer", CHINESE JOURNAL OF CANCER RESEARCH = CHUNG-KUO YEN CHENG YEN CHIU, CHINA, 1 October 2014 (2014-10-01), China , pages 558 - 563, XP055439490, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220261/pdf/cjcr-26-05-558.pdf> [retrieved on 20180110], DOI: 10.3978/j.issn.1000-9604.2014.10.05 *
OH, K.S. ; SOTO, D.E. ; SMITH, D.C. ; MONTIE, J.E. ; LEE, C.T. ; SANDLER, H.M.: "Combined-Modality Therapy With Gemcitabine and Radiation Therapy as a Bladder Preservation Strategy: Long-Term Results of a Phase I Trial", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS., PERGAMON PRESS., USA, vol. 74, no. 2, 1 June 2009 (2009-06-01), USA , pages 511 - 517, XP026094986, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2008.08.021 *
SHARIAT, S. F. et al. 'Update on intravesical agents for non-invasive bladder cancer' Immunotherapy,2010 May 2(3):381-92 *
STERNBERG ITAY A ET AL: JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 190, no. 5, 7 May 2013 (2013-05-07), pages 1686 - 1691, XP028734145, ISSN: 0022-5347, DOI: 10.1016/J.JURO.2013.04.120 *

Also Published As

Publication number Publication date
SI3452053T1 (sl) 2023-03-31
NZ787786A (en) 2025-10-31
EP4209221A1 (en) 2023-07-12
JP2024028881A (ja) 2024-03-05
EP3452053A1 (en) 2019-03-13
PL3452053T3 (pl) 2023-05-08
SG11201809838VA (en) 2018-12-28
KR102435709B1 (ko) 2022-08-25
MX389296B (es) 2025-03-20
RU2764747C2 (ru) 2022-01-20
MX2021013461A (es) 2021-12-10
RU2022100624A (ru) 2022-02-09
EP3452053B1 (en) 2022-12-14
AU2017261371A1 (en) 2018-12-13
RU2018142908A (ru) 2020-06-08
KR20220123317A (ko) 2022-09-06
EP3452053A4 (en) 2019-12-25
RU2018142908A3 (enExample) 2020-08-31
FI3452053T3 (fi) 2023-04-12
SMT202300047T1 (it) 2023-03-17
HUE060965T2 (hu) 2023-04-28
PT3452053T (pt) 2023-03-03
JP2022009327A (ja) 2022-01-14
WO2017193098A1 (en) 2017-11-09
CA3023274A1 (en) 2017-11-09
IL262746B (en) 2022-09-01
BR112018072551A2 (pt) 2019-02-19
NZ748252A (en) 2025-10-31
JP2019514970A (ja) 2019-06-06
RS64032B1 (sr) 2023-04-28
IL262746A (en) 2018-12-31
SG10201913416PA (en) 2020-03-30
MX2018013432A (es) 2019-08-12
KR20190005204A (ko) 2019-01-15
ES2940227T3 (es) 2023-05-04
IL295592A (en) 2022-10-01
US20190388338A1 (en) 2019-12-26
JP7712055B2 (ja) 2025-07-23
NZ787824A (en) 2025-10-31
CN109475571A (zh) 2019-03-15
CN118453872A (zh) 2024-08-09
LT3452053T (lt) 2023-02-10
HRP20221544T1 (hr) 2023-02-17

Similar Documents

Publication Publication Date Title
AU2017261371B2 (en) Method of treating lower tract urothelial cancer
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
US12059428B2 (en) Methods of treating tumor metastasis
AU2018366106B2 (en) Methods of treatment and maintenance therapy for bladder cancer using gemcitabine
HK40005970B (en) Method of treating lower tract urothelial cancer
HK40005970A (en) Method of treating lower tract urothelial cancer
BR122024005298A2 (pt) Usos de antimetabólitos no tratamento de câncer urotelial do trato inferior, kits e dispositivo de liberação
BR112018072551B1 (pt) Kits para tratamento de câncer de bexiga músculo invasivo
KR20250000043A (ko) 나노입자, 이의 제조 방법 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR122025013571A2 (pt) Usos de trópsio no tratamento de bexiga hiperativa e dispositivos intravesicais

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)